Leukemia Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Leukemia
| Protocol | Alliance A041501 |
|---|---|
| Cancer Type: | NEWLY DIAGNOSED PRECURSOR B-CELL ALL |
| Fast Facts |
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
| Protocol | SWOG S1318 |
|---|---|
| Cancer Type: | (Ph-) ALL |
| Fast Facts |
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A041701 |
|---|---|
| Cancer Type: | ACUTE MYELOID LEUKEMIA |
| Fast Facts |
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A041702 |
|---|---|
| Cancer Type: | Chronic Lymphocytic Leukemia (CLL) |
| Fast Facts |
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 YEARS OF AGE) with Chronic Lymphocytic Leukemia (CLL)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1712 |
|---|---|
| Cancer Type: | Chronic Myeloid Leukemia (CML) |
| Fast Facts |
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | NHLBI-MDS |
|---|---|
| Cancer Type: | Myelodysplastic Syndromes |
| Fast Facts |
The National Myelodysplastic Syndromes (MDS) Study
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A231602CD |
|---|---|
| Cancer Type: | CCDR |
| Fast Facts |
Assessing Financial Difficulty in Patients with Blood Cancers
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | COG ACCL16N1CD |
|---|---|
| Cancer Type: | Acute Lymphoblastic Leukemia (ALL) |
Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult AYA Acute Lymphoblastic Leukemia ALL
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
